Jubilant Pharmova Ltd.

The global Sterile Injectable Drugs market is projected to reach $1.4 Trillion by 2030, driven by personalized medicine, biologics, biosimilars, and advanced manufacturing. Key growth factors include R&D investments, complex drug formulations, and quality assurance. The report provides detailed market analysis, competitive insights, and future trends.

The Pharmaceutical Contract Manufacturing Market is projected to exceed $155 billion in 2024, driven by high in-house drug development costs and varying regulatory requirements. CDMOs like Thermo Fisher Scientific and Samsung Biologics are expanding services to meet demand, offering end-to-end solutions from development to commercial-scale manufacturing. The market report provides revenue forecasts to 2034, regional and national market analyses, and profiles of leading companies.

Jubilant Biosys offers Pierre Fabre a put option to acquire 80% equity in a new French company, Jasmin SAS, to take over PF's R&D Centre at Saint Julien, enhancing Jubilant's global CRO services and European market presence.